The Role of the HCP Community in Increasing Public Awareness of RSV Disease in all Infants

Scott Kober discusses the role of the health care community in raising public awareness about the risk and prevention of respiratory syncytial virus, or RSV, in all infants, as well as some of the promising scientific research in this area.

Scott Kober sits down with Dr. Joseph Domachowske, professor of pediatrics, professor of microbiology and immunology, and director of the Global Maternal-Child and Pediatric Health Program at SUNY Upstate Medical University.


Center for Disease Control and Prevention. RSV in infants and young children. Available at: Accessed March 2022.Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) in US infants, 1997 to 2000. J Pediatr. 2003;143(5):127-132. doi:10.1067/s0022-3476(03)00510-9Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Seasonal respiratory syncytial virus – United States, 2014-2017. MMWR Morb Mortal Wkly Rep. 2018;67(2):71-76.Arriola C, Kim L. Estimated burden of community-induced respiratory syncytial virus hospitalizations in children <2 years in the United States 2014-15. J Pediatric Infect Dis Soc. 2020; 9587-595.Rainisch G, Adhikari B, Meltzer MI, Langley G. Estimation of the impact of multiple immunization products on medically treated respiratory syncytial virus (RSV) infections in infants. Vaccine. 2020;38(2):251-257. doi:10.1016/j.vaccine.2019.10.023Centers for Disease Control and Prevention. The National Respiratory and Enteric Virus Surveillance System (NREVSS). RSV National Trends. Respiratory syncytial virus (RSV). † Available at: Accessed March 2022. Cohen R, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune culpability of the COVID-19 pandemic in childhood, how can we close the immunity gap? Infectious diseases now. 2021; 51:418-423. for Disease Control and Prevention. Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States. Available at: Accessed March 2022.NSW Health. COVID-19 WEEKLY SURVEILLANCE IN NSW. Available at: Accessed March 2022. Public Health England. Weekly National Influenza and COVID-19 Surveillance Report Week 3 Report (up to Week 2 data). Available at: Accessed March 2022.Zheng Z, Pitzer VE, Shapiro ED, Bont LJ, Weinberger DM. Estimation of the timing and intensity of respiratory syncytial virus recurrence after the US COVID-19 pandemic. JAMA network. 2021;4(12):e2141779. doi:10.1001/jamanetworkopen.2021.41779.Karron RA. Plotkin vaccines. Seventh Edition. Chapter 51, Respiratory syncytial virus vaccines. Elsevier Inc. 2018.Hall CB. The nascent burden of respiratory syncytial virus in children. Infect Disord Drug Targets. 2012; 12(2):92-7. Heylen E, Neyts J, Jochmans D. Drug candidates and model systems in the discovery of antiviral drugs for respiratory syncytial virus. Biochem Pharmacol. 2017; 127:1-12. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatrician Rev. 2014;35(12):519-30.Krilov LR, Fergie J, Goldstein M, Brannman L. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations Among Premature Infants . Ben J Perinatol. 2020;37(2):174-183. doi:10.1055/s-0039-1694008Zhou H, Thompson WW, Viboud CG, et al. Hospital admissions associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54(10):1427-1436. doi:10.1093/cid/cis211Domachowske J, Halczyn J, Bonville C. Prevention of pediatric respiratory syncytial virus infection. Pediatrician Ann. 2018;47(9). doi: 10.3928/19382359-20180816-01Viguria N, Martínez-Baz I, Moreno-Galarraga L, Sierrasesúmaga L, Salcedo B, et al. (2018) Hospitalization with respiratory syncytial virus in children in northern Spain. PLOS ONE 13(11): e0206474., D., & Blais, FX (1991). Post-viral bronchial hyperreactivity syndrome: Recognizing the great mimicry of asthma. The Journal of the American Osteopathic Association, 91(5), 465-475.Fauroux B, Simões EAF, Checchia PA, et al. The burden and prolonged respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 2017;6(2):173-197. doi:10.1007/s40121-017-0151-4Wenzel, SE. Gibbs, RL, Lehr, MV, Simoes, EAF. Respiratory outcomes in high-risk children 7 to 10 years after respiratory syncytial virus immunoglobulin prophylaxis. The American Journal of Medicine. 2002; (112) 8: P627-633. DOI: Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV): transmission. Available from: Accessed March 2022. Assaker R, Colas AE, Julien-Marsollier F, et al. Presenting symptoms of COVID-19 in children: a meta-analysis of published studies. Br J Anaesth. 2020;125(3):e330-e332. doi:10.1016/j.bja.200.05.026external icon.

Comments are closed.